{"id":"W3011685940","doi":"10.1200/jco.2012.30.15_suppl.tps6634","title":"Dasatinib plus SMO antagonist versus dasatinib alone for treating patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): Design of CA180-363, a phase II, open-label randomized trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Dasatinib; Medicine; Smoothened; Internal medicine; Tolerability; Imatinib; Clinical endpoint; Imatinib mesylate; Oncology; Phases of clinical research; Nilotinib; Myeloid leukemia; Pharmacology; Clinical trial; Hedgehog signaling pathway; Adverse effect; Signal transduction; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001952281,0.002703633,0.003499622,0.0006328603,0.0004470874,0.001365955,0.001229714,0.002291252,0.009595848],"category_scores_gemma":[0.001457549,0.0009576128,0.002036302,0.0005545206,0.00147455,0.001869374,0.0006105987,0.004083979,0.002116757],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009234524,"about_ca_system_score_gemma":0.00143454,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007072479,"about_ca_topic_score_gemma":0.001912881,"domain_scores_codex":[0.9992679,0.000337153,0.00004690191,0.0001540451,0.00004930503,0.0001447029],"domain_scores_gemma":[0.9991637,0.0001574304,0.0001719241,0.00005370923,0.00004615221,0.0004071783],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9820307,0.007515733,0.0003896327,0.000290761,0.0003783966,0.00003313347,0.00003423238,0.000306753,0.002602581,0.0001014589,0.0005020577,0.005814461],"study_design_scores_gemma":[0.9082376,0.08955989,0.0006580016,0.00001245502,0.0002552102,0.00002918671,0.00001623601,0.000362098,0.0002611261,0.000172364,0.0004238459,0.00001192209],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.9810331,0.002304368,0.0006258401,0.001178083,0.0007995043,0.01006429,0.001445101,0.0001406871,0.002409092],"genre_scores_gemma":[0.9775819,0.002128078,0.001883915,0.001618851,0.0006923493,0.01005565,0.001301887,0.00003343766,0.004703907],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.009595848,"threshold_uncertainty_score":0.03210127,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1380904361321535,"score_gpt":0.4571903452712565,"score_spread":0.319099909139103,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}